… in predicting prognosis in head and neck cancer. In particular, the … The most promising gene
panel test for cancer is the … standard treatment are subject to a gene panel test for cancer, so …

… In head and neck oncology, cetuximab that targets epidermal growth factor … molecular
targeted therapy in HNSCC and to discuss how it could be accelerated by exploiting the molecular …

… To obtain the best experience, we recommend you use a … and the only available targeted
therapy, and subsequent … and to develop more effective targeted therapies. However, as …

… ) with cisplatin and radiotherapy has reported promising 2-year progression free survival
and … Therefore, further investigations, particularly in targeted therapy, are needed. PI3K/AKT/…

… So far, the most promising treatment is a combination of … the efficacy of immunotherapy
and molecular targeted treatments. … Immunotherapy for head and neck cancer offers patients, …

… will be key to develop more effective targeted therapies with less toxicity and high specificity.
… have a promising prognosis. However, the mainstays of treatment for advanced tumors are …

… The elevated expression of EGFR in OSCC makes it an attractive molecular target for
treatment. Cetuximab, is an approved targeted therapy for HNSCC, including advanced OSCC. …

… cancer, it was natural to assume that head and neck cancer patients may benefit from
EGFR-targeted therapies… a hopeful finding. Currently there are no clinical trials using Osimertinib …

… of the microenvironment of head and neck cancer with … L1 therapy with targeting other
receptors such as lectin-like inhibitory receptor NKG2A or EGFR seems to be promising for therapy …

… While these cancers are conventionally defined as members of the family of head and neck
cancers, they are generally thought of as different entities from HNSCC. The main reasons …